[go: up one dir, main page]

MX9203291A - Metodo para acoplamiento de liposomas. - Google Patents

Metodo para acoplamiento de liposomas.

Info

Publication number
MX9203291A
MX9203291A MX9203291A MX9203291A MX9203291A MX 9203291 A MX9203291 A MX 9203291A MX 9203291 A MX9203291 A MX 9203291A MX 9203291 A MX9203291 A MX 9203291A MX 9203291 A MX9203291 A MX 9203291A
Authority
MX
Mexico
Prior art keywords
liposomas
coupling method
coupling
liposomas coupling
Prior art date
Application number
MX9203291A
Other languages
English (en)
Inventor
Helen Loughrey
Pieter R Cullis
Marcel B Bally
Lewis S Choi
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06759419 external-priority patent/US4880635B1/en
Priority claimed from US06/941,913 external-priority patent/US4885172A/en
Priority claimed from US07/370,650 external-priority patent/US5059421A/en
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of MX9203291A publication Critical patent/MX9203291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
MX9203291A 1985-06-26 1992-06-24 Metodo para acoplamiento de liposomas. MX9203291A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US74916185A 1985-06-26 1985-06-26
US06759419 US4880635B1 (en) 1984-08-08 1985-07-26 Dehydrated liposomes
US81103785A 1985-12-18 1985-12-18
US06/941,913 US4885172A (en) 1985-06-26 1986-12-15 Composition for targeting, storing and loading of liposomes
US07/370,650 US5059421A (en) 1985-07-26 1989-06-23 Preparation of targeted liposome systems of a defined size distribution
US41277989A 1989-09-26 1989-09-26

Publications (1)

Publication Number Publication Date
MX9203291A true MX9203291A (es) 1992-08-01

Family

ID=27559867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203291A MX9203291A (es) 1985-06-26 1992-06-24 Metodo para acoplamiento de liposomas.

Country Status (2)

Country Link
US (1) US5399331A (es)
MX (1) MX9203291A (es)

Families Citing this family (452)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113369A1 (en) * 1991-01-16 2003-06-19 Martin Francis J. Liposomes with enhanced circulation time and method of treatment
US5540935A (en) * 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
WO1997031624A1 (en) * 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
US5780319A (en) * 1996-04-19 1998-07-14 Pasteur Sanofi Diagnostics Immunoassays to detect antiphospholipid antibodies
US5776487A (en) * 1996-04-19 1998-07-07 Pasteur Sanofi Diagnostics Liposome reagents for immunoassays
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
WO1998017242A1 (en) * 1996-10-24 1998-04-30 Board Of Trustees Of The University Of Illinois Unique peptides for targeting fibronectin-enriched surfaces and a method for their delivery in the treatment of metastatic cancer
WO1999018946A1 (en) 1997-10-14 1999-04-22 Tatton Nadine A Methods for increasing schwann cell survival
US20020137786A1 (en) * 1998-02-12 2002-09-26 William G. Tatton Deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
US6329356B1 (en) * 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
MXPA01010835A (es) * 1999-04-28 2003-07-14 Univ Kingston Composiciones y metodos para tratar amiloidosis.
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
ATE354655T1 (de) 1999-08-24 2007-03-15 Medarex Inc Humane antikörper gegen ctla-4 und deren verwendungen
CA2406343A1 (en) * 2000-04-13 2001-10-25 Emory University Antithrombogenic membrane mimetic compositions and methods
ATE553131T1 (de) 2000-05-08 2012-04-15 Celldex Res Corp Humane monoklonale antikörper gegen dendritische zellen
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
AU2001283055A1 (en) * 2000-07-28 2002-02-13 Emory University Biological component comprising artificial membrane
US7045283B2 (en) * 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
WO2002055021A2 (en) * 2001-01-12 2002-07-18 Univ Emory Glycopolymers and free radical polymerization methods
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
CA2443644A1 (en) * 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
US20040110439A1 (en) * 2001-04-20 2004-06-10 Chaikof Elliot L Native protein mimetic fibers, fiber networks and fabrics for medical use
US20030138975A1 (en) * 2001-12-20 2003-07-24 Kimberly-Clark Worldwide, Inc. Diagnostic signal amplification with proteinoid microspheres
US7056535B2 (en) * 2001-12-20 2006-06-06 Kimberly-Clark Worldwide, Inc. Triggered release from proteinoid microspheres
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
PT2336318E (pt) 2002-11-13 2013-06-12 Genzyme Corp Modulação anti-sentido da expressão de apolipoproteína b
EP2336318B1 (en) 2002-11-13 2013-04-24 Genzyme Corporation Antisense modulation of apolipoprotein b expression
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2417634A1 (en) * 2002-11-22 2004-05-22 Emory University Plastic and elastic protein copolymers
EP1631590B1 (en) 2003-04-23 2011-07-27 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2862535B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
PT1691837E (pt) 2003-12-10 2012-08-27 Medarex Inc Anticorpos ip-10 e suas utilizações
SI2418220T1 (sl) 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alfa protitelesa in njihova uporaba
EP1713900A4 (en) * 2004-01-27 2009-06-17 Compugen Ltd METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
US7833978B2 (en) 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
US20090156668A1 (en) * 2004-03-19 2009-06-18 The Trustees Of Columbia University In The City Of New York Ginkgolide Compounds, Compositions, And Extracts, And Uses Thereof
US7824672B2 (en) * 2004-03-26 2010-11-02 Emory University Method for coating living cells
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DK1781705T3 (en) 2004-06-21 2015-01-12 Squibb & Sons Llc Interferon-alpha receptor 1 antibodies and uses thereof
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
US20060110441A1 (en) * 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
CA2629751A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
EP1828111A2 (en) * 2004-11-12 2007-09-05 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
EP1817305A2 (en) * 2004-11-16 2007-08-15 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006081631A1 (en) * 2005-02-07 2006-08-10 Lipotek Pty Ltd Adjuvanting material
US8207303B2 (en) 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US20110135725A1 (en) * 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US20220110870A1 (en) * 2005-05-23 2022-04-14 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
KR20080032097A (ko) 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 씨디19 항체 및 그의 용도
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EA016186B1 (ru) 2005-09-26 2012-03-30 Медарекс, Инк. Человеческие моноклональные антитела к cd70 и их применение
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PL1960434T3 (pl) 2005-12-08 2012-12-31 Squibb & Sons Llc Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1
BRPI0620819A2 (pt) * 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
ES2396569T3 (es) 2006-01-17 2013-02-22 Medarex, Inc. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo y xilosilo
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
WO2008033847A2 (en) * 2006-09-11 2008-03-20 Emory University Modified protein polymers
SI2486941T1 (sl) 2006-10-02 2017-08-31 E. R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo CXCR4 in njihova uporaba
MX2009003635A (es) * 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
ES2533463T3 (es) 2006-10-12 2015-04-10 Bhi Limited Partnership Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
PE20080857A1 (es) * 2006-10-20 2008-08-19 Amgen Inc Formulaciones a base de polipeptidos estables
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
AU2007334264A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
US20080213282A1 (en) * 2006-12-21 2008-09-04 Jaby Jacob Formulations
WO2008086431A1 (en) * 2007-01-09 2008-07-17 Biova, L.L.C. A method of separating components of technical eggs, edible eggs, yolk and whites and products therefrom
DK2716301T3 (en) 2007-02-16 2017-07-31 Merrimack Pharmaceuticals Inc ANTIBODIES AGAINST ERBB3 AND APPLICATIONS THEREOF
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CA2680237C (en) 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
WO2009032845A2 (en) 2007-09-04 2009-03-12 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US20100080773A1 (en) * 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
ES2663077T3 (es) 2007-11-02 2018-04-11 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
EP2650017A3 (en) 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
WO2009100309A2 (en) 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
PT2274331E (pt) 2008-05-02 2014-02-27 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
CA2725911A1 (en) * 2008-05-30 2009-12-23 Dana-Farber Cancer Institute, Inc. Methods of treating a meiotic kinesin-associated disease
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
EP2342356A4 (en) 2008-09-29 2012-11-21 Univ Ben Gurion AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF
JP2012505900A (ja) 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
LT2403878T (lt) 2009-03-05 2017-10-10 E. R. Squibb & Sons, L.L.C. Pilnai žmogaus specifiniai antikūnai, skirti cadm1
SG10201401604VA (en) 2009-04-20 2014-08-28 Oxford Biotherapeutics Ltd Antibodies Specific To Cadherin-17
JP2012524524A (ja) 2009-04-27 2012-10-18 ノバルティス アーゲー ＩＬ−１２レセプターβ１サブユニットに特異的な治療用抗体の組成物および使用方法
CA2758290C (en) 2009-04-27 2018-04-10 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
CA2761203A1 (en) 2009-05-04 2010-11-11 Abbott Research B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2507265B1 (en) 2009-12-01 2016-05-11 Compugen Ltd. Antibody specific for heparanase splice variant T5 and its use.
EP2513309A2 (en) 2009-12-18 2012-10-24 Novartis AG Organic compositions to treat hsf1-related diseases
CN102939303A (zh) 2009-12-22 2013-02-20 诺瓦提斯公司 四价cd47-抗体恒定区融合蛋白用于治疗
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP3153521B1 (en) 2010-03-26 2019-09-04 Trustees of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
AR081082A1 (es) 2010-04-23 2012-06-06 Novartis Ag Composiciones organicas para tratar enfermedades relacionadas con beta-enac
MX2012012441A (es) 2010-05-04 2013-02-26 Merrimack Pharmaceuticals Inc Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos.
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
AU2011248124B2 (en) 2010-05-05 2016-07-21 The Board Of Trustees Of The University Of Illinois Compounds and methods of treating brain disorders
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2016030888A1 (en) 2014-08-26 2016-03-03 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
WO2012001647A2 (en) 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
US8642038B2 (en) 2010-07-02 2014-02-04 Rembrandt Enterprises, Inc. Isolated egg protein and egg lipid materials, and methods for producing the same
US8916156B2 (en) 2010-07-02 2014-12-23 Rembrandt Enterprises, Inc. Isolated egg protein and egg lipid materials, and methods for producing the same
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
CN103339127A (zh) 2010-08-24 2013-10-02 Sgc制药股份有限公司 盐化合物
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
SG10201603034TA (en) 2011-04-15 2016-05-30 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN103619353B (zh) 2011-06-02 2016-01-06 戴埃克斯有限公司 Fc受体结合蛋白
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
MX2013014789A (es) 2011-06-16 2014-01-20 Novartis Ag Proteinas solubles para utilizarse como productos terapeuticos.
MY177267A (en) 2011-06-28 2020-09-10 Berlin Chemie Ag Antibodies
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
PL2726099T3 (pl) 2011-07-01 2018-12-31 Novartis Ag Sposób leczenia zaburzeń metabolicznych
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
BR112014005103A2 (pt) 2011-09-02 2017-07-04 Novartis Ag composições orgânicas para tratar doenças associadas com hsf1
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
SG11201402783YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
BR112014013568A2 (pt) 2011-12-05 2017-06-13 Novartis Ag anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
EP2793940B1 (en) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogate binding proteins
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
BR112014018481A2 (pt) 2012-02-01 2017-07-04 Compugen Ltd anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
DK2814829T3 (en) 2012-02-13 2017-03-20 Bristol Myers Squibb Co RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2703540T3 (es) 2012-06-04 2019-03-11 Novartis Ag Métodos de marcación específicos del sitio y moléculas producidas de este modo
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP2892558B1 (en) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
HK1216428A1 (zh) 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
MY174820A (en) 2012-12-18 2020-05-17 Novartis Ag Stabilized insulin-like growth factor polypeptides
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
MX2015010146A (es) 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
MA38322B1 (fr) 2013-02-08 2018-09-28 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
EP3611189A1 (en) 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
EP2836515A1 (en) 2013-03-14 2015-02-18 AbbVie Inc. Low acidic species compositions and methods for producing and using the same
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
JP6333943B2 (ja) 2013-03-15 2018-05-30 ノバルティス アーゲー 抗体薬物コンジュゲート
EP4001275B1 (en) 2013-06-26 2024-11-27 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for the treatment of cancer
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
CA2926173A1 (en) 2013-10-02 2015-04-09 Novartis Ag Insulin-like growth factor mimetics for use in therapy
RS61620B1 (sr) 2013-10-11 2021-04-29 Oxford Bio Therapeutics Ltd Konjugovana antitela prema ly75 za lečenje kancera
AU2014348676B2 (en) 2013-11-13 2020-06-18 Bristol-Myers Squibb Company Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
SI3712174T1 (sl) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Protitelesa in delci proti VISTA
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US9499800B2 (en) 2013-12-26 2016-11-22 Regents Of The University Of Minnesota Methods of making and using chemically self assembled-nanorings
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
EP3848057B1 (en) 2014-01-21 2025-12-10 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
AU2015229463A1 (en) 2014-03-12 2016-09-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
CN107257691B (zh) 2014-07-16 2021-09-21 达娜-法勃肿瘤研究所公司 低级别浆液性卵巢癌中的her3抑制
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
BR112017001588A2 (pt) 2014-08-12 2017-11-21 Novartis Ag conjugados de anticorpo/fármaco anti-cdh6
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP2993174A1 (en) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
EP3217982B1 (en) 2014-11-10 2025-05-28 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
AU2015347015B2 (en) 2014-11-14 2019-02-14 Novartis Ag Antibody drug conjugates
DK3221346T3 (da) 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
ES2941895T3 (es) 2014-11-25 2023-05-26 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18F del dominio de fibronectina tipo (III)
CA2969067A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
EP3227341A1 (en) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
CN108367003B (zh) 2014-12-12 2022-01-21 麻省总医院 乳腺癌脑转移的治疗
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
EP3945096A1 (en) 2014-12-19 2022-02-02 Regenesance B.V. Antibodies that bind human c6 and uses thereof
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
JP6676058B2 (ja) 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
TW201632202A (zh) 2015-01-30 2016-09-16 諾華公司 乳癌之治療
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US20180298110A1 (en) 2015-03-30 2018-10-18 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
CN107921090A (zh) 2015-04-06 2018-04-17 苏伯多曼有限责任公司 含有从头结合结构域的多肽及其用途
JP2018510913A (ja) 2015-04-10 2018-04-19 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 抗ウイルス剤としての使用のためのピロン誘導体
EP3294773A1 (en) 2015-05-15 2018-03-21 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2016188932A2 (en) 2015-05-22 2016-12-01 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Combination compositions and their use in methods for treating obesity and obesity-related disorders
DK3303396T5 (da) 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
KR20180021833A (ko) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
CA2991980A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
CN109071648B (zh) 2015-10-23 2022-07-19 辉瑞有限公司 抗il-2抗体及其组合物和用途
CN108738324B (zh) 2015-11-19 2022-06-21 百时美施贵宝公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
AR108824A1 (es) 2015-11-21 2018-10-03 Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
JP6849694B2 (ja) 2015-11-30 2021-03-24 ブリストル−マイヤーズ スクウィブ カンパニー 抗ヒトｉｐ−１０抗体およびそれらの使用
DK3383920T3 (da) 2015-11-30 2024-04-02 Univ California Levering af tumorspecifik nyttelast og immunaktivering ved hjælp af et humant antistof rettet mod et meget specifikt tumorcelleoverfladeantigen
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
ES2847155T3 (es) 2016-01-21 2021-08-02 Novartis Ag Moléculas multiespecíficas que fijan como objetivo CLL-1
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
AU2017219254B2 (en) 2016-02-17 2019-12-12 Novartis Ag TGFbeta 2 antibodies
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
US10894835B2 (en) 2016-03-04 2021-01-19 The Rockefeller University Antibodies to CD40 with enhanced agonist activity
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
EP3442579A4 (en) 2016-04-15 2019-12-18 Immunext Inc. ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
US20190153425A1 (en) 2016-04-22 2019-05-23 Biontech Rna Pharmaceuticals Gmbh Methods for Providing Single-Stranded RNA
WO2017201111A1 (en) 2016-05-19 2017-11-23 Bristol-Myers Squibb Company Pet-imaging immunomodulators
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
EP3463486A1 (en) 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
US20180002417A1 (en) 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
BR112019000431A2 (pt) 2016-07-14 2019-07-09 Bristol-Myers Squibb Company anticorpos contra tim3 e usos dos mesmos
CN109641911B (zh) 2016-08-19 2023-02-21 百时美施贵宝公司 seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
EP3305781A1 (en) 2016-10-07 2018-04-11 Deutsches Krebsforschungszentrum Chemical substances which inhibit the enzymatic activity of human kallikrein-related peptidase 6 (klk6)
CU20210030A7 (es) 2016-10-13 2021-11-04 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika
CN110267971B (zh) 2016-11-07 2023-12-19 百时美施贵宝公司 免疫调节剂
US12049511B2 (en) 2016-11-10 2024-07-30 Fortis Therapeutics, Inc. Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
CN110312736B (zh) 2017-01-23 2023-05-09 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
CA3055561A1 (en) 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
KR20200003915A (ko) 2017-05-10 2020-01-10 알바후나 테라퓨틱스, 에스.엘. 높은 이중 ＨＩＶ 항바이러스 활성과 면역조절 활성을 갖는 Ｆｃ-융합 단백질 유도체
US11168129B2 (en) 2017-05-15 2021-11-09 University Of Rochester Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
CN110719915A (zh) 2017-05-25 2020-01-21 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
WO2018233333A1 (zh) 2017-06-23 2018-12-27 苏州博聚华生物医药科技有限公司 一种靶向人肿瘤干细胞的单克隆抗体及其应用
JP7206222B2 (ja) 2017-06-23 2023-01-17 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－１のアンタゴニストとして作用する免疫調節剤
AU2018318319A1 (en) 2017-08-18 2020-02-20 Adrx, Inc. Tau aggregation peptide inhibitors
JP2020531041A (ja) 2017-08-28 2020-11-05 上海易楽生物技術有限公司 ポリペプチドとポリペプチドに結合される抗体
WO2019070643A1 (en) 2017-10-03 2019-04-11 Bristol-Myers Squibb Company IMMUNOMODULATORS
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
CN111278865B (zh) 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
EP3704159A1 (en) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
JP7430137B2 (ja) 2017-11-02 2024-02-09 オックスフォード バイオセラピューティクス リミテッド 抗体および使用方法
AU2018369639C1 (en) 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
MX2020004935A (es) 2017-11-14 2020-09-25 Arcellx Inc Terapias con celulas inmunitarias multifuncionales.
US11433132B2 (en) 2017-12-01 2022-09-06 Novartis Ag Polyomavirus neutralizing antibodies
EP3717516A1 (en) 2017-12-01 2020-10-07 Pfizer Inc Anti-cxcr5 antibodies and compositions and uses thereof
PL3710484T3 (pl) 2017-12-20 2024-03-25 Harbour Biomed (Shanghai) Co., Ltd Przeciwciała wiążące ctla-4 i ich zastosowania
US20200339591A1 (en) 2017-12-21 2020-10-29 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
EP3728200A1 (en) 2017-12-21 2020-10-28 Gliapharm SA Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
MX2020010871A (es) 2018-03-15 2020-11-09 BioNTech SE Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US20220064274A1 (en) 2018-03-26 2022-03-03 Shanghai Yile Biotechnology Co., Ltd. Use of probdnf regulator in b cell-related diseases
KR102826439B1 (ko) 2018-03-29 2025-06-26 화이자 인코포레이티드 Lfa3 변이체 및 그의 조성물 및 용도
AR117566A1 (es) 2018-04-02 2021-08-18 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y sus usos
JP2021521182A (ja) 2018-04-12 2021-08-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
CN112292185B (zh) 2018-04-17 2025-07-29 塞德斯医疗公司 抗cd27和抗pd-l1抗体及双特异性构建体
US12139480B2 (en) 2018-04-20 2024-11-12 Iomx Therapeutics Ag 5-thiazolecarboxamide kinase inhibitor and uses thereof
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
EP3801766A1 (en) 2018-05-31 2021-04-14 Novartis AG Hepatitis b antibodies
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
CA3111339A1 (en) 2018-07-10 2020-01-16 Rush University Medical Center Use of immunomodulators to control infection and stimulate healing in normal and diabetic wounds
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
CN112533954B (zh) 2018-08-08 2024-06-18 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和her2的重组双功能蛋白
JP7585193B2 (ja) 2018-08-30 2024-11-18 武田薬品工業株式会社 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
TW202024131A (zh) 2018-09-07 2020-07-01 美商輝瑞大藥廠 抗-αvβ8抗體及組合物及其用途
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
EP3856244A4 (en) 2018-09-28 2022-07-20 Jochen Reiser SUPAR AND PREDICTION AND TREATMENT OF ACUTE KIDNEY LESION
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
US12410185B2 (en) 2018-10-23 2025-09-09 Myelopro Diagnostics And Research Gmbh Compounds targeting mutant calreticulin
EP3643713B1 (en) 2018-10-23 2025-07-30 iOmx Therapeutics AG Heterocyclic kinase inhibitors and uses thereof
JP7520003B2 (ja) 2018-11-16 2024-07-22 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
EP4406555A3 (en) 2018-12-21 2024-11-06 Novartis AG Antibodies to pmel17 and conjugates thereof
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
AU2020234394B2 (en) 2019-03-08 2024-02-15 AbTis Co., Ltd. Site-specific antibody conjugation and antibody-drug conjugate as specific example thereof
JP2022525164A (ja) 2019-03-14 2022-05-11 武田薬品工業株式会社 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
US12291562B2 (en) 2019-04-01 2025-05-06 Rush University Medical Center Reagents and assays using modified integrin domains
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
KR20220010535A (ko) 2019-05-21 2022-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
BR112021024997A2 (pt) 2019-07-03 2022-01-25 Oxford Biotherapeutics Ltd Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso
BR112022000319A2 (pt) 2019-07-11 2022-03-15 Kahr Medical Ltd Heterodímeros e métodos de uso dos mesmos
CN114174536A (zh) 2019-07-15 2022-03-11 百时美施贵宝公司 抗trem-1抗体及其用途
JP2022540904A (ja) 2019-07-15 2022-09-20 ブリストル－マイヤーズ スクイブ カンパニー ヒトｔｒｅｍ－１に対する抗体およびその使用
JP7671739B2 (ja) 2019-09-06 2025-05-02 ノバルティス アーゲー 治療用融合タンパク質
EP4051692A1 (en) 2019-10-30 2022-09-07 Bristol-Myers Squibb Company Immunomodulators
EP4061818B1 (en) 2019-11-19 2023-12-06 Bristol-Myers Squibb Company Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases
US20230055711A1 (en) 2020-01-03 2023-02-23 Biosion Inc. Antibodies binding bcma and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
WO2021141682A1 (en) 2020-01-06 2021-07-15 Bristol-Myers Squibb Company Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases
US12403174B2 (en) 2020-01-06 2025-09-02 Bristol-Myers Squibb Company Immunomodulators
JP2023510854A (ja) 2020-01-13 2023-03-15 武田薬品工業株式会社 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
CN119708230A (zh) 2020-02-27 2025-03-28 正大天晴药业集团股份有限公司 结合il4r的抗体及其用途
EP4110407A1 (en) 2020-02-28 2023-01-04 Bristol-Myers Squibb Company Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
KR20220155332A (ko) 2020-03-16 2022-11-22 브리스톨-마이어스 스큅 컴퍼니 면역조정제
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
JP2023519930A (ja) 2020-04-01 2023-05-15 ユニバーシティ オブ ロチェスター インフルエンザｈ３ｎ２ウイルスのヘマグルチニン（ｈａ）およびノイラミニダーゼ（ｎａ）に対するモノクローナル抗体
US20230174674A1 (en) 2020-04-04 2023-06-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
EP3901151A1 (en) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
EP4143191A2 (en) 2020-04-28 2023-03-08 iOmx Therapeutics AG Bicyclic kinase inhibitors and uses thereof
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
EP4143224A1 (en) 2020-05-01 2023-03-08 Novartis AG Immunoglobulin variants
EP4143236A1 (en) 2020-05-01 2023-03-08 Novartis AG Engineered immunoglobulins
WO2021226460A1 (en) 2020-05-08 2021-11-11 Bristol-Myers Squibb Company Immunomodulators
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021237109A1 (en) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
FR3112939B1 (fr) 2020-07-31 2024-01-05 Univ Montpellier Produit universel de thérapie cellulaire et son utilisation
JP2023534765A (ja) 2020-08-07 2023-08-10 フォーティス セラピューティクス，インク． 免疫複合体を標的とするｃｄ４６およびその使用方法
EP4221841A1 (en) 2020-10-02 2023-08-09 Bristol-Myers Squibb Company Macrocyclic peptide boronate immunomodulators
US20230374073A1 (en) 2020-10-08 2023-11-23 Bristol-Myers Squibb Company Dimeric milla immunomodulators
WO2022076796A1 (en) 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Macrocyclic immunomodulators
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
WO2022097061A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
AU2021380005A1 (en) 2020-11-11 2023-06-01 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
US20240199701A1 (en) 2021-03-24 2024-06-20 Bristol-Myers Squibb Company Immunomodulators
MX2023011110A (es) 2021-03-26 2023-11-23 Arcellx Inc Terapias de celulas inmunitarias multifuncionales.
BR112023020303A2 (pt) 2021-04-09 2023-11-14 Celldex Therapeutics Inc Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
US20240261367A1 (en) 2021-04-12 2024-08-08 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
CA3219316A1 (en) 2021-05-26 2022-12-01 Christian Rohlff Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
CN117425666A (zh) 2021-06-09 2024-01-19 百时美施贵宝公司 环肽免疫调节剂
WO2022258792A1 (en) 2021-06-09 2022-12-15 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel anti-fibrotic drugs
WO2023288213A1 (en) 2021-07-12 2023-01-19 Bristol-Myers Squibb Company Macrocyclic immunomodulators
US20240409585A1 (en) 2021-07-19 2024-12-12 Bristol-Myers Squibb Company Macrocyclic immunomodulators
CN113773401B (zh) 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
EP4408468A4 (en) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc MULTIPLE FORMATS OF MOLECULAR COMPLEXES
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
EP4417626A4 (en) 2021-10-14 2025-10-22 Latticon Suzhou Biopharmaceuticals Co Ltd NOVEL ANTIBODY-CYTOKINE FUSION PROTEIN, ITS PREPARATION METHOD AND USE
JP2024540950A (ja) 2021-10-20 2024-11-06 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
CN118119642A (zh) 2021-10-28 2024-05-31 诺华股份有限公司 工程化Fc变体
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
JP2024540451A (ja) 2021-11-18 2024-10-31 オックスフォード バイオセラピューティックス リミテッド 組合せ医薬
JP2024544009A (ja) 2021-12-03 2024-11-26 ブリストル－マイヤーズ スクイブ カンパニー 大員環免疫調節剤
WO2023105281A1 (en) 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
US20250333485A1 (en) 2022-01-27 2025-10-30 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
IL315208A (en) 2022-02-24 2024-10-01 Sinomab Bioscience Ltd Bispecific binding proteins against alarmins and uses thereof
WO2023173393A1 (zh) 2022-03-18 2023-09-21 北京天广实生物技术股份有限公司 结合b7-h3的抗体及其用途
JP2025511189A (ja) 2022-03-28 2025-04-15 ブリストル－マイヤーズ スクイブ カンパニー 大環状免疫調節剤
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors
CA3255838A1 (en) 2022-04-26 2023-11-02 Novartis Ag MULTISPECIFIC ANTIBODIES TARGETTING IL-13 AND IL-18
WO2023217987A1 (en) 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
EP4526323A1 (en) 2022-05-20 2025-03-26 Bristol-Myers Squibb Company Macrocyclic immunomodulators
CN117186238A (zh) 2022-05-31 2023-12-08 宜明昂科生物医药技术（上海）股份有限公司 靶向pd-l1和vegf的重组融合蛋白及其制备和用途
WO2024059472A1 (en) 2022-09-12 2024-03-21 Bristol-Myers Squibb Company Macrocyclic immunomodulators
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
AU2024233763A1 (en) 2023-03-03 2025-10-16 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024188356A1 (en) 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof
WO2024218322A1 (en) 2023-04-21 2024-10-24 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Ferroptosis inhibitors
CN121311508A (zh) 2023-06-09 2026-01-09 徕特康(苏州)生物制药有限公司 抗her2互补性双特异抗体-药物偶联物及其制备方法和用途
CN121358773A (zh) 2023-06-12 2026-01-16 南京蓬勃生物科技有限公司 结合人ccr8的抗体及其用途
CN117224483B (zh) * 2023-09-01 2024-05-10 山东京卫制药有限公司 一种适用于热辅助治疗的硝酸2-(4-甲基噻唑-5-基)乙酯盐脑靶向脂质体
WO2025083076A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025082594A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
TW202535931A (zh) 2024-03-05 2025-09-16 美商澤納仕生物製藥股份有限公司 ＴＮＦａ抗體之穩定調配物及其用途
WO2025193583A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193574A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193571A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193573A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025229127A1 (en) 2024-04-30 2025-11-06 Iomx Therapeutics Ag A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
EP4643861A1 (en) 2024-04-30 2025-11-05 iOmx Therapeutics AG A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4743560A (en) * 1984-03-26 1988-05-10 Becton Dickinson And Company Solid phase assay
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
CA1264668C (en) * 1984-06-20 1990-01-23 EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES
EP0211042A1 (en) * 1985-01-18 1987-02-25 Cooper-Lipotech, Inc. Liposome composition and method
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral

Also Published As

Publication number Publication date
US5399331A (en) 1995-03-21

Similar Documents

Publication Publication Date Title
MX9203291A (es) Metodo para acoplamiento de liposomas.
NO167412C (no) Kopling.
FI864213A0 (fi) Datastyrt system foer vaetskebehandlings- och reaktionskarakterisering.
FI865007A0 (fi) Industriellt system foer avloppsluft.
FI870638A0 (fi) Uppvaermningsapparat foer under tryck staoende oeverfoeringsvaetska.
DE3650198D1 (de) Mehrplattenspielersystem.
DE3676603D1 (de) Gelenkkupplung.
FI873077L (fi) Faestanordning foer stomipaose.
FI870004L (fi) Vingsegelsystem.
FR2586768B1 (fr) Embrayage.
FI862387A0 (fi) Karbonfritt system innefattande enbart loesningsmedel innehaollande mikrokapslar.
FI870643A7 (fi) Tislauslaite.
DE3687172D1 (de) Multiplexuebertragungssystem.
DE3683474D1 (de) Numerisierungsverfahren.
DE3685761D1 (de) Multiplexuebertragungssystem.
FI861404L (fi) Barnstol foer aokdon.
DE3685159D1 (de) Magnetische uebertragungsmethode.
FI861751L (fi) Reparationsfoerfarande foer en defekt traeskiva.
DE3676753D1 (de) Stranggiessverfahren.
ES2012353B3 (es) Embrague ralentizador.
DE3681759D1 (de) Abschreckverfahren.
FI861233A0 (fi) Efterbehandlad prostetisk anordning.
NO167425C (no) Koblingslist.
FI860978L (fi) Spjaelgaller foer saengar.
FI860439L (fi) Serietransmissionsanordning.